Biotechnology News MAXALT Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-10 out of 10 found

Current Search: maxalt: 10

Merck Experimental Migraine Drug Proves Better Than Zomag In Late-Stage Study
(FinancialWire) Merck & Co.'s (NYSE: MRK) experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC's (NYSE: AZN) Zomig treatment in a late-stage study, but was better tolerated.

Telcagepant works...

TMC Net: Jul 1 2008 6:50AM
Matching: maxalt

Find similar documents

Telcagepant works...

Calibre Macro World: Jul 1 2008 3:26AM
Matching: maxalt

Find similar documents

TradingMarkets: Jul 1 2008 3:18AM
Matching: maxalt

Find similar documents

Merck migraine drug matches rival's medication
NEW YORK -- Merck & Co's experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC's Zomig treatment in a late-stage study, but was better tolerated, Merck said.

Favourable phase 3 data for Merck's...

Business Spectator: Jun 28 2008 12:48AM
Matching: maxalt

Find similar documents

Merck migraine drug matches Zomig in study
NEW YORK (Reuters) - Merck (nyse: MRK - news - people ) & Co's experimental treatment for migraine headaches provided similar pain relief to AstraZeneca PLC (nyse: AZN - news - people )'s Zomig treatment in a late-stage study, but was...

Forbes.com: Jun 27 2008 5:41PM
Matching: maxalt

Find similar documents

Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f
4:10 PM ET DUBLIN, Ireland--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to...

Business Week: Jun 18 2008 11:43AM
Matching: maxalt

Find similar documents

Pharmaceutical Pricing and Distribution in Japan Incorporates All Pricing Rule Changes That Came into Effect f
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b2dd9e/pharmaceutical_pri) has announced the addition of the 'Pharmaceutical Pricing and Distribution in Japan: The keys to success in the...

Business Wire via Yahoo!: Jun 18 2008 10:42AM
Matching: maxalt

Find similar documents

FDA approves Teva's generic migraine drug
Rizatriptan benzoate is a generic version of Merck's migraine pain treatment Maxalt tablets, equivalent to 5mg and 10mg base.

FDA approves Teva's generic migraine drug.

Pharmaceutical Business Review: Apr 19 2008 3:04AM
Matching: maxalt

Find similar documents

Teva Pharmaceutical gets tentative FDA OK for generic Maxalt tablets
BOSTON (Thomson Financial) - Teva Pharmaceutical Industries Ltd.

said Thursday it has received tentative approval from the Food and Drug Administration for the company's abbreviated new drug application to market its generic version of...

Sharewatch: Apr 17 2008 1:14PM
Matching: maxalt

Find similar documents

Teva Pharma's generic migraine drug tentatively approved
NEW YORK (AP) - Generic drug maker Teva Pharmaceutical Industries Ltd.

said Thursday the Food and Drug Administration tentatively approved its version of Merck & Co.'s Maxalt migraine pain tablets.

The Israeli company said it...

Sharewatch: Apr 17 2008 1:41PM
Matching: maxalt

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.